Helixgate

Helixgate

Uncategorized

Lilly buys non-opioid pain drugmaker 4E

Published

on

It’s the latest in a string of deals for Lilly, which has sunk more than $18 billion into acquisitions over the past few years.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

PwC declares biopharma ecosystem ‘back to full health’ as M&A buoys sector

Published

on

Precision science is ruling the M&A scene as pharmas prepare for loss of exclusivity on key products, PwC says in a new report. Biotechs should be prepared with a dual-track process with the IPO window now open.

Continue Reading

Uncategorized

A new Westlake-backed biotech takes aim at migraines

Vedana Therapeutics emerged from stealth Wednesday with $46 million to support its mission of developing “anti-PACAP” therapies, an increasingly popular strategy for migraine prevention. 

Read More

Published

on

Vedana Therapeutics emerged from stealth Wednesday with $46 million to support its mission of developing “anti-PACAP” therapies, an increasingly popular strategy for migraine prevention. 

Read More

Continue Reading

Uncategorized

Putting the wrong foot forward: 5 tricky interview questions

Published

on

Even something as simple as “Tell me about yourself” can trip up biopharma professionals during job interviews. Two recruiting experts discuss what candidates should and shouldn’t say when answering five specific questions.

Continue Reading
Advertisement

Trending